头孢哌酮舒巴坦钠治疗慢性阻塞性肺炎急性加重期的临床疗效及对呼吸功能的影响  

Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in the Treatment of Acute Exacerbation of Chronic Obstructive Pneumonia and its Effect on Respiratory Function

作　　者：万英凤 WAN Yingfeng(Pharmacy Department of Fengxin County People's Hospital,Fengxin 330700,Jiangxi,China)

机构地区：[1]奉新县人民医院药剂科,江西奉新330700

出　　处：《医学信息》2024年第19期118-121,共4页Journal of Medical Information

摘　　要：目的 观察头孢哌酮舒巴坦钠治疗慢性阻塞性肺炎急性加重期的临床疗效及对呼吸功能的影响。方法 选取2022年4月-2023年4月在我院诊治的72例慢性阻塞性肺炎急性加重期患者为研究对象,采用随机数字表法分为对照组和观察组,各组36例。对照组采用头孢他啶治疗,观察组采用头孢哌酮舒巴坦钠治疗,比较两组临床疗效、呼吸功能指标[血氧饱和度(SaO_(2))、氧分压(PaO_(2))、二氧化碳分压(PaCO_(2))]、临床症状(肺部啰音、咳嗽、呼吸急促)评分及不良反应发生率。结果 观察组治疗总有效率(94.44%)高于对照组(80.56%)(P<0.05);两组SaO_(2)、PaO_(2)均高于治疗前,PaCO_(2)均低于治疗前,且观察组SaO_(2)、PaO_(2)均高于对照组,PaCO_(2)低于对照组(P<0.05);观察组肺部啰音、咳嗽、呼吸急促评分均低于对照组(P<0.05);观察组不良反应发生率低于对照组(P<0.05)。结论 头孢哌酮舒巴坦钠治疗慢性阻塞性肺炎急性加重期的临床疗效确切,可显著改善患者呼吸功能,减轻临床症状,且治疗安全性相对较高,值得临床应用。Objective To observe the clinical efficacy of cefoperazone sodium and sulbactam sodium in the treatment of acute exacerbation of chronic obstructive pneumonia disease and its effect on respiratory function.Methods A total of 72 patients with acute exacerbation of chronic obstructive pneumonia disease diagnosed and treated in our hospital from April 2022 to April 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 36 patients in each group.The control group was treated with ceftazidime,and the observation group was treated with cefoperazone sodium and sulbactam sodium.The clinical efficacy,respiratory function indexes[blood oxygen saturation(SaO_(2)),oxygen partial pressure(PaO_(2)),carbon dioxide partial pressure(PaCO_(2))],clinical symptoms(pulmonary rales,cough,shortness of breath)scores and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group(94.44%)was higher than that in the control group(80.56%)(P<0.05).SaO_(2) and PaO_(2) in the two groups were higher than those before treatment,PaCO_(2) was lower than that before treatment,and SaO_(2) and PaO_(2) in the observation group were higher than those in the control group,PaCO_(2) was lower than that in the control group(P<0.05).The scores of pulmonary rales,cough and shortness of breath in the observation group were lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Cefoperazone sodium and sulbactam sodium is effective in the treatment of acute exacerbation of chronic obstructive pneumonia,which can significantly improve the respiratory function of patients,reduce clinical symptoms,and the safety of treatment is relatively high.It is worthy of clinical application.

关 键 词：头孢哌酮舒巴坦钠 慢性阻塞性肺炎急性加重期 呼吸功能 

分 类 号：R563[医药卫生—呼吸系统]